rs4810485 — CD40

Intronic variant in CD40 regulating B-cell surface expression; the G allele drives higher CD40 levels and is shared risk across rheumatoid arthritis, SLE, Crohn's disease, and multiple sclerosis

See your personal result for CD40

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CD40 — The B-Cell Activation Rheostat

CD40 is a transmembrane receptor expressed on B cells, monocytes, dendritic cells, and other antigen-presenting cells. When its ligand CD40L (CD154) — displayed on activated T helper cells — binds CD40, it triggers a cascade that drives B-cell proliferation, antibody class switching, and germinal center formation. In plain terms, CD40 is the molecular handshake between T cells and B cells that tells the immune system to mount a full adaptive response. The variant rs4810485, located in intron 1 of the CD40 gene, acts as a rheostat: the G allele keeps the dial turned up, driving higher CD40 expression; the T allele turns it down.

The Mechanism

rs4810485 sits within a regulatory region of the first intron of CD40. Studies using electrophoretic mobility shift assays in synovial fibroblasts and immune cells have shown allele-specific binding at this exact position11 allele-specific binding at this exact position
The G allele creates a stronger protein-binding signal than the T allele across multiple cell types including Jurkat (T cells), HT1080 (fibroblasts), and primary immune cells. Preliminary evidence from a Letter implicates RBPJ, the canonical effector of NOTCH signaling22 NOTCH signaling
NOTCH is a cell-cell communication pathway that controls differentiation and activation thresholds in immune cells, as a candidate binding factor. If confirmed, the G allele may create a binding site that recruits RBPJ more efficiently, elevating CD40 transcription.

The downstream consequence is measurable and consistent: compared with the GG genotype, individuals carrying GT or TT genotypes show significantly reduced CD40 mRNA and protein expression33 significantly reduced CD40 mRNA and protein expression
Both basal and stimulated conditions tested in CD14+ monocytes and CD19+ B cells in peripheral blood B cells and monocytes. This is not a subtle effect — GG homozygotes have approximately 33% more CD40 on the surface of primary human B lymphocytes than TT homozygotes.

The Evidence

Rheumatoid Arthritis: The CD40 locus was identified as an RA susceptibility locus in a GWAS meta-analysis of 3,393 cases and 12,462 controls44 GWAS meta-analysis of 3,393 cases and 12,462 controls
Analysis combined multiple genome-wide studies and applied replication in 3,929 ACPA-positive RA cases and 5,807 controls (OR 0.87, p=8.2×10⁻⁹ for the T allele — the T allele is protective). A large UK replication study55 large UK replication study
3,962 UK RA patients versus 3,531 healthy controls recruited across five centres confirmed the association (OR 0.86 per T allele, p=7.8×10⁻⁸ after meta-analysis).

Beyond disease onset, rs4810485 influences disease course: TT homozygotes show higher rates of joint destruction in ACPA-positive RA66 higher rates of joint destruction in ACPA-positive RA
Primary cohort of 563 RA patients; ACPA-positive subset used; replicated in 393 ACPA-positive patients in NARAC cohort (p=0.003, replicated in an independent cohort at p=0.021), making it one of the first non-HLA genetic severity factors replicated in RA.

Systemic Lupus Erythematosus: In a combined Greek and Turkish cohort, the T allele was significantly under-represented in SLE patients77 the T allele was significantly under-represented in SLE patients
509 SLE patients and 825 healthy controls across two cohorts (combined OR 0.63, 95% CI 0.53–0.74, p=2×10⁻⁸), with the same allele-specific expression pattern found in cases and controls alike.

Crohn's Disease and Multiple Sclerosis: rs4810485 is in tight linkage disequilibrium (r²=0.95) with rs1883832, a CD40 promoter variant. Studies of rs1883832 showed a novel association with Crohn's disease88 novel association with Crohn's disease
Spanish cohort genotyped for rs1883832; CD patients vs population controls (OR 1.19, p=0.002) and replication in multiple sclerosis susceptibility (OR 1.12, p=0.025). Notably, the susceptibility allele for RA/SLE appears protective in MS — the CD40 locus shows disease-specific directional effects, implying that the optimal level of CD40 signaling differs across distinct autoimmune processes.

Graves' Disease and Therapeutic Relevance: In a precision medicine study of Graves' disease patients treated with iscalimab (an anti-CD40 monoclonal antibody), treatment responders were enriched for the G-allele haplotype99 treatment responders were enriched for the G-allele haplotype
13 Graves disease patients treated with iscalimab; genotyped for rs4810485 and flanking CD40 SNPs while non-responders predominantly carried T-allele haplotypes (p=0.0008). This provides proof-of-concept that rs4810485 genotyping may one day guide selection of anti-CD40 pathway therapies.

Practical Actions

For GG carriers, the elevated CD40 expression on B cells creates the foundation for heightened autoimmune B-cell activity. The key implication is not a single actionable nutrient or supplement, but rather a set of monitoring priorities: early detection of autoimmune conditions, awareness of how anti-CD40L biologics may be particularly relevant if they are ever prescribed, and avoidance of exposures known to trigger autoimmunity in genetically predisposed individuals.

For TT homozygotes, the reduced CD40 expression appears protective against most autoimmune diseases studied — but the picture is complex. In multiple sclerosis, the low-CD40 T allele may increase susceptibility, and in RA patients who carry the TT genotype, evidence suggests faster joint destruction despite lower disease onset risk. TT carriers should still be monitored for RA if symptoms develop, as the TT genotype does not fully eliminate risk.

Interactions

CD40 rs4810485 acts within the broader adaptive immune network. The most relevant co-regulatory variants in the database are rs2476601 (PTPN22 R620W, affecting T-cell signaling threshold) and rs3087243 (CTLA4 CT60, the T-cell checkpoint). In individuals who carry risk alleles at multiple nodes of T-cell/B-cell co-stimulation, the combined dysregulation may be substantially greater than any single variant predicts. Functional studies specifically on the CD40–PTPN22 and CD40–CTLA4 combined effects are limited, but these variants all converge on the same germinal center reaction pathway. Future compound action entries in this category will capture these combined interactions when supported by published evidence.

Genotype Interpretations

What each possible genotype means for this variant.

TT Low CD40 Expression Normal

Two T alleles associated with reduced CD40 expression and lower susceptibility to most CD40-driven autoimmune diseases

The TT genotype produces the lowest CD40 surface expression because the T allele creates a weaker binding site for the RBPJ transcription factor that drives CD40 transcription. With less CD40 on B cells, the threshold for productive B-cell activation is higher, making it harder for autoreactive cells to escape tolerance. This translates to measurable protection: in RA, two T alleles reduce disease risk with an approximate OR of 0.76 (0.87² for additive two-allele effect). In SLE, the combined OR across Greek and Turkish cohorts was 0.63 for T allele carriers.

An important caveat: the protective effect of TT is not universal across all autoimmune conditions. In multiple sclerosis, the low-CD40 T allele may modestly increase susceptibility (OR ~1.12 per allele based on rs1883832 data in LD with rs4810485). The direction of effect reverses for MS, suggesting that CD40 costimulation plays different roles depending on whether autoimmunity targets peripheral joints, the thyroid, kidneys, or the central nervous system. TT carriers are not immune to RA — other genetic and environmental factors contribute substantially.

Additionally, despite lower disease onset risk in RA, TT carriers who do develop ACPA-positive RA show faster joint destruction compared to GT and GG carriers in at least one large cohort study. This paradox is not yet fully explained but may reflect that TT carriers who overcome the protective threshold face a distinct immunological phenotype once disease begins.

GT Intermediate CD40 Expression Intermediate

One G and one T allele producing intermediate CD40 expression and moderately elevated autoimmune risk

The codominant/additive architecture of this locus means that each G allele adds incrementally to CD40 expression. With one G allele, you have roughly intermediate CD40 surface density on B cells and antigen-presenting cells. This places your autoimmune susceptibility in the moderate range — meaningfully elevated compared to TT, but not at the level of GG carriers who face the highest risk for conditions like seropositive RA and SLE. In populations studied, the T allele has an odds ratio of approximately 0.87 per allele for RA protection, meaning each T allele reduces RA risk by about 13%.

GG High CD40 Expression High Risk

Two G alleles driving elevated CD40 surface expression; increased susceptibility to rheumatoid arthritis, SLE, and Graves' disease

The GG genotype drives the highest transcriptional output from the CD40 gene via RBPJ-mediated NOTCH signaling. B cells from GG donors respond more vigorously to CD40L stimulation, proliferate more robustly, and class-switch antibodies more readily. This is the molecular basis for the elevated autoimmune disease risk: when CD40 is overexpressed, autoreactive B cells that would normally be silenced can escape tolerance checkpoints. In rheumatoid arthritis, elevated CD40 on synovial B cells contributes to the production of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor that drive joint inflammation and destruction. In SLE, hyperactivated B cells produce anti-dsDNA and other nuclear antibodies that deposit in kidneys, skin, and joints.

The GG genotype also has preliminary therapeutic implications: in a small Graves' disease study (n=13), GG-haplotype carriers showed preferential response to iscalimab anti-CD40 therapy, while T-allele carriers were non-responders (p=0.0008). Although the sample size limits definitive conclusions, as anti-CD40 and anti-CD40L biologics advance through clinical trials for RA, SLE, and other conditions, GG genotype may emerge as a predictive biomarker for treatment selection.